BioPharmSignal logoBioPharmSignal

Biotech News

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Praxis Precision Medicines (PRAX)Praxis Precision MedicinesEarnings

BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the second quarter ended June 30, 2026 and

Related news

PRAXPraxis Precision Medicines2026-08-06 12:00 EST

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

ECORelectroCore2026-07-30 12:00 EST

electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026

ABOSAcumen Pharmaceuticals2026-08-05 20:00 EST

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

TNXPTonix Pharmaceuticals2026-07-27 11:00 EST

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

XERSXeris Pharmaceuticals2026-07-23 11:30 EST

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

HRMYHarmony Biosciences2026-07-21 12:05 EST

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

AXSMAxsome2026-07-14 11:00 EST

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

TSHATaysha Gene Therapies2026-08-04 20:00 EST

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

ALKSAlkermes plc2026-07-14 20:00 EST

Alkermes to Report Second Quarter Financial Results on July 28, 2026

View all latest news

Praxis Precision Medicines

Precision Neuroscience Praxis Precision Medicines develops therapies for genetically and physiologically defined disorders of neuronal excitation. Its pipeline spans movement disorders and developmental epilepsies. Ulixacaltamide Ulixacaltamide is a small-molecule T-type calcium-channel modulator under FDA review for essential...

Recent company news

PRAXPraxis Precision Medicines2026-08-06 12:00 EST

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PRAXPraxis Precision Medicines2026-08-04 20:01 EST

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRAXPraxis Precision Medicines2026-07-30 20:01 EST

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

PRAXPraxis Precision Medicines2026-07-07 12:00 EST

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

PRAXPraxis Precision Medicines2026-07-02 20:01 EST

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
370.16 USD
Market cap
7.19B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States